From October 1, 2022 to December 31, 2022, the company has repurchased 0 shares, representing 0% for ?0 million. With this, the company has completed the repurchase of 2,052,808 shares, representing 3.72% for ?135.01 million under the buyback announced on November 3, 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
83.8 EUR | -0.59% | +3.92% | +38.87% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+38.87% | 4.67B | |
+33.25% | 699B | |
+27.56% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+15.08% | 236B | |
+4.89% | 198B | |
-10.10% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.